Neurogene Inc. (NGNE)

NASDAQ: NGNE · USD

$30.4

+3.43 (+12.7%)· Recorded snapshot

Market cap	608.7M
Net income (ttm)	-111.1M
EPS (ttm)	-$5.04
Shares out	20M
Volume	554,854
Beta	2.09

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -111.1M
EPS (ttm): -$5.04
Market cap: 608.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-45.3

P25 n/aP50 n/aP75 n/a

ROIC-29.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NGNE indicators

Market & fundamental data

Available fields

167

Groups with data

Currency

USD

Showing 167 of 167 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001404644
Company name	Neurogene Inc.
Country	United States
Country code	US
CUSIP number	64135M105
Earnings date	2026-11-12
Earnings time	amc
Employees	131
Employees change	24
Employees growth	22.43%
Enterprise value	$391.7M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2003
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US64135M1053
Last 10-K release date	2026-03-24
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$608.7M
Market cap category	Small-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$30.42
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	NGNE
U.S. state	New York
Website	https://www.neurogene.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-16.58%
FCF / EV yield	-22.67%
FCF yield	-14.52%
P/B ratio	1.97x
Price / tangible book value	2.78x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-848,168
ROA	-27.97%
ROCE	-54.4%
ROE	-45.32%
ROIC	-29.73%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-890,000
Depreciation and amortization	$3.2M
EBIT	$-121.2M
EBITDA	$-118M
EPS	$-5.04
FCF per share	$-4.38
Financing cash flow	$36.5M
Free cash flow	$-87.7M
Free cash flow minus SBC	$-105.9M
Gross profit	$-88.4M
Investing cash flow	$103.9M
Net borrowing	$-43,000
Net cash flow	$53.7M
Net income	$-111.1M
Operating cash flow minus SBC	$-105M
Operating income	$-121.2M
Stock-based compensation	$18.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$13.72
Debt / equity	0.04
Interest coverage	-40,409
Long-term assets	$15.5M
Long-term liabilities	$5.7M
Net cash (debt)	$217M
Net cash / market cap	35.94%
Net cash growth	-17.65%
Net debt / equity	-1
Piotroski F-Score	1
Property, plant and equipment	$14M
Shareholders' equity	$217.1M
Tangible book value	$217.1M
Tangible book value per share	$13.72
Total assets	$244.4M
Total cash	$225.4M
Total debt	$8.3M
Total liabilities	$27.2M
WACC	15.52%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$228.9M
Current liabilities	$21.5M
Current ratio	10.64
Net working capital	$-15M
Quick ratio	10.5
Working capital	$207.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-12.28%
Dividend yield	0%
Shareholder yield	-12.28%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$30.48
1D price change	12.71%
1M price change	6.25%
1M total return	6.25%
1W price change	18.43%
1W total return	18.43%
1Y price change	-6.18%
1Y return CAGR	-6.18%
1Y total return	-6.18%
20-day SMA	$25.12
200-day SMA	$27.71
3M price change	-13.11%
3M total return	-13.11%
50-day SMA	$31.15
50-day SMA vs 200-day SMA	50over200
52-week high	$43.66
52-week high date	2026-07-09
52-week low	$15.93
52-week low date	2026-02-05
6M price change	11.2%
6M total return	11.2%
All-time high	$74.49
All-time high date	2024-11-11
All-time low	$6.88
All-time low date	2025-04-08
Average true range (ATR)	$2.37
Average volume	349.4K
Beta (1Y)	2.67
Beta (2Y)	3.15
Beta (5Y)	2.09
Change from 52-week high	-30.33%
Change from 52-week low	90.96%
Change from all-time high	-59.62%
Change from all-time low	337.53%
Change from open	15.89%
Day's gap	-2.74%
Dollar volume	$16.9M
High price	$30.84
Low price	$26.14
Monthly RSI	54.88
Open price	$26.25
Position in 52-week range	91.06%
Premarket change	0.3%
Premarket close	$26.99
Premarket price	$27.07
Previous close	$26.99
Price vs 150-day SMA	-1.32%
Price vs 20-day SMA	19.75%
Price vs 200-day SMA	8.54%
Price vs 50-day SMA	-3.43%
Relative volume	1.59
RSI	58.93
Sharpe ratio	0.26
Sortino ratio	0.47
Volume	554.9K
Weekly RSI	51.14
YTD price change	46.02%
YTD total return	46.02%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	11.3M
Float percentage	56.47%
Shares change (QoQ)	1.1%
Shares change (YoY)	12.28%
Shares held by insiders	7.01%
Shares held by institutions	61%
Shares outstanding	20M
Short % of float	44.02%
Short % of shares	24.86%
Short ratio	16.1 days

Deeper analysis on NGNE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NGNE report

Is a complete NGNE research report available?

No complete published report is available for Neurogene Inc. (NGNE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Neurogene Inc. (NGNE)

Price

Financial snapshot

Fair-value bridge

Latest news · NGNE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NGNE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NGNE

Frequently asked questions